{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T04:09:28Z","timestamp":1767499768047},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40256-019-00325-9","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T01:43:16Z","timestamp":1550194996000},"page":"249-257","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cardiovascular Protection with Anti-hyperglycemic Agents"],"prefix":"10.1007","volume":"19","author":[{"given":"Prakash","family":"Deedwania","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tushar","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"issue":"10","key":"325_CR1","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146\u2013603.","journal-title":"Circulation"},{"issue":"8","key":"325_CR2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/aje\/kwf111","volume":"156","author":"SH Saydah","year":"2002","unstructured":"Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol. 2002;156(8):714\u20139.","journal-title":"Am J Epidemiol"},{"key":"325_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837\u201353.","journal-title":"Lancet"},{"issue":"5","key":"325_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2337\/dc15-2322","volume":"39","author":"MG Wong","year":"2016","unstructured":"Wong MG, Perkovic V, Chalmers J, ADVANCE-ON Collaborative Group, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care. 2016;39(5):694\u2013700.","journal-title":"Diabetes Care"},{"key":"325_CR5","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med"},{"key":"325_CR6","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","volume":"52","author":"FM Turnbull","year":"2009","unstructured":"Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288\u201398.","journal-title":"Diabetologia"},{"key":"325_CR7","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/S0140-6736(14)60611-5","volume":"384","author":"HC Gerstein","year":"2014","unstructured":"Gerstein HC, Miller ME, Ismail-Beigi F, et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet. 2014;384:1936\u201341.","journal-title":"Lancet"},{"key":"325_CR8","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","volume":"372","author":"RA Hayward","year":"2015","unstructured":"Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197\u2013206.","journal-title":"N Engl J Med"},{"key":"325_CR9","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"325_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","volume":"370","author":"RM Lago","year":"2007","unstructured":"Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129\u201336.","journal-title":"Lancet"},{"key":"325_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1056\/NEJMoa073394","volume":"357","author":"PD Home","year":"2007","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes\u2014an interim analysis. N Engl J Med. 2007;357:28\u201338.","journal-title":"N Engl J Med"},{"key":"325_CR12","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457\u201371.","journal-title":"N Engl J Med"},{"key":"325_CR13","unstructured":"Department of Health and Human Services, Food and Drug Administration. Guidance for industry: diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. \n                    http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm071627.pdf\n                    \n                  . Accessed 15 Jul 2017."},{"key":"325_CR14","unstructured":"European Medicines Agency guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. London: Committee for Medicinal Products for Human Use; 2012."},{"key":"325_CR15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMp1309610","volume":"369","author":"WR Hiatt","year":"2013","unstructured":"Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs\u2014insights from the rosiglitazone experience. N Engl J Med. 2013;369:1285\u20137.","journal-title":"N Engl J Med"},{"issue":"3","key":"325_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.dsx.2016.09.003","volume":"11","author":"A Gupta","year":"2017","unstructured":"Gupta A, Jelinek HF, Al-Aubaidy H. Glucagon like peptide-1 and its receptor agonists: their roles in management of type 2 diabetes mellitus. Diabetes Metab Syndr. 2017;11(3):225\u201330.","journal-title":"Diabetes Metab Syndr"},{"key":"325_CR17","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/CIRCRESAHA.116.305665","volume":"116","author":"J Zhong","year":"2015","unstructured":"Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res. 2015;116:1491\u2013504.","journal-title":"Circ Res"},{"key":"325_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, SAVOR-TIMI 53 Steering Committee and Investigators, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med"},{"key":"325_CR19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, EXAMINE Investigators, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327\u201335.","journal-title":"N Engl J Med"},{"key":"325_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, TECOS Study Group, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232\u201342.","journal-title":"N Engl J Med"},{"issue":"9982","key":"325_CR21","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC, EXAMINE Investigators, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067\u201376.","journal-title":"Lancet."},{"key":"325_CR22","unstructured":"FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM493965.pdf\n                    \n                  . Accessed 21 Jul 17."},{"key":"325_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/14740338.2016.1221402","volume":"15","author":"D Cimmaruta","year":"2016","unstructured":"Cimmaruta D, Maiorino MI, Scavone C, et al. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert Opin Drug Saf. 2016;15:77\u201383.","journal-title":"Expert Opin Drug Saf"},{"key":"325_CR24","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.2337\/dc11-0291","volume":"34","author":"MC Bunck","year":"2011","unstructured":"Bunck MC, Corner A, Eliasson B, et al. Effects of exenatide on measures of beta-cell function after 3\u00a0years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011;34:2041\u20137.","journal-title":"Diabetes Care"},{"key":"325_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/dme.12594","volume":"32","author":"BJ Scholten Von","year":"2015","unstructured":"Von Scholten BJ, Lajer M, Goetze JP, Persson F, Rossing P. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med. 2015;32:343\u201352.","journal-title":"Diabet Med"},{"key":"325_CR26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","volume":"12","author":"GG Sokos","year":"2006","unstructured":"Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694\u20139.","journal-title":"J Card Fail"},{"key":"325_CR27","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","volume":"109","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962\u20135.","journal-title":"Circulation"},{"key":"325_CR28","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","volume":"33","author":"J Lonborg","year":"2012","unstructured":"Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491\u20139.","journal-title":"Eur Heart J"},{"key":"325_CR29","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K Ban","year":"2008","unstructured":"Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor dependent and -independent pathways. Circulation. 2008;117:2340\u201350.","journal-title":"Circulation"},{"key":"325_CR30","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.amjmed.2010.11.004","volume":"124","author":"R Chilton","year":"2011","unstructured":"Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagon like peptide-1-based therapies. Am J Med. 2011;124:S35\u201353.","journal-title":"Am J Med"},{"key":"325_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24:15\u201330.","journal-title":"Cell Metab"},{"key":"325_CR32","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, ELIXA Investigators, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247\u201357.","journal-title":"N Engl J Med"},{"key":"325_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, LEADER Steering Committee, LEADER Trial Investigators, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"325_CR34","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, SUSTAIN-6 Investigators, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"issue":"13","key":"325_CR35","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, EXSCEL Study Group, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med."},{"key":"325_CR36","doi-asserted-by":"publisher","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, REWIND Trial Investigators, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2017. \n                    https:\/\/doi.org\/10.1111\/dom.13028\n                    \n                  \n                           (Epub ahead of print).","DOI":"10.1111\/dom.13028"},{"issue":"21","key":"325_CR37","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jacc.2017.04.014","volume":"69","author":"N Sattar","year":"2017","unstructured":"Sattar N, Petrie MC, Zinman B, Januzzi JL Jr. Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol. 2017;69(21):2646\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"325_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1210\/er.2010-0029","volume":"32","author":"MA Abdul-Ghani","year":"2011","unstructured":"Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515\u201331.","journal-title":"Endocr Rev"},{"key":"325_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ejps.2016.08.025","volume":"93","author":"T Madaan","year":"2016","unstructured":"Madaan T, Akhtar M, Najmi AK. Sodium glucose cotransporter 2 (SGLT2) inhibitors: current status and future perspective. Eur J Pharm Sci. 2016;93:244\u201352.","journal-title":"Eur J Pharm Sci"},{"key":"325_CR40","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.4239\/wjd.v6.i11.1186","volume":"6","author":"RA Sanchez","year":"2015","unstructured":"Sanchez RA, Sanabria H, de Los Santos C, Ramirez AJ. Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease. World J Diabetes. 2015;6:1186\u201397.","journal-title":"World J Diabetes"},{"key":"325_CR41","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","volume":"36","author":"E Ferrannini","year":"2015","unstructured":"Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36:2288\u201396.","journal-title":"Eur Heart J"},{"issue":"4","key":"325_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, EMPA-REG OUTCOME Investigators, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med."},{"key":"325_CR43","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"325_CR44","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016;37:1526\u201334.","journal-title":"Eur Heart J"},{"key":"325_CR45","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057977\n                    \n                  . Accessed 9 Oct 2017."},{"issue":"7","key":"325_CR46","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, CANVAS Program Collaborative Group, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"key":"325_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.012","volume":"200","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)\u2013TIMI 58 Trial. Am Heart J. 2018;200:83\u20139.","journal-title":"Am Heart J"},{"key":"325_CR48","doi-asserted-by":"publisher","unstructured":"Wiviott SD, Raz I, Bonaca MP, DECLARE\u2013TIMI 58 Investigators, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018. \n                    https:\/\/doi.org\/10.1056\/nejmoa1812389\n                    \n                  \n                           (Epub ahead of print).","DOI":"10.1056\/nejmoa1812389"},{"issue":"3","key":"325_CR49","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, CVD-REAL Investigators and Study Group, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249\u201359.","journal-title":"Circulation"},{"issue":"23","key":"325_CR50","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","volume":"71","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Lam CSP, Kohsaka S, CVD-REAL Investigators and Study Group, et al. Lower Cardiovascular risk associated with SGLT-2i in >\u2009400,000 patients: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628\u201339.","journal-title":"J Am Coll Cardiol"},{"key":"325_CR51","unstructured":"FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) [news release]. FDA\u2019s website. \n                    https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm557507.htm?source\u2009=\u2009govdelivery&utm_medium\u2009=\u2009email&utm_source\u2009=\u2009govdelivery\n                    \n                  . Accessed 8 Oct 2017."},{"issue":"Suppl. 1","key":"325_CR52","first-page":"S86","volume":"41","author":"Cardiovascular disease and risk management","year":"2018","unstructured":"Cardiovascular disease and risk management. Standards of medical care in diabetes\u20142018. Diabetes Care. 2018;41(Suppl. 1):S86\u2013104.","journal-title":"Diabetes Care"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-019-00325-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T00:08:50Z","timestamp":1581725330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-019-00325-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1007\/s40256-019-00325-9","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]},"assertion":[{"value":"15 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Deedwania has served as a consultant\/speaker for Janssen Pharmaceuticals. Dr. Acharya has no potential conflicts of interest that might be relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}